Molcure

What Molcure does

MOLCURE Inc. is a Tokyo-based (Kawasaki, Kanagawa) AI-driven drug discovery company founded in 2013 that builds proprietary biological foundation models and applies them to antibody and peptide design for pharmaceutical and biotechnology partners. Its core platform integrates a proprietary Antibody LLM built from scratch for biological sequence data, physics-based simulations, and an in-house wet-lab loop (directed evolution, next-generation sequencing, and HAIVE laboratory automation) operating across two Japanese facilities in Kawasaki and the Tsuruoka Science Park. The company has accumulated over 1 billion proprietary antibody and peptide datapoints and reports claimed performance advantages of 10x shorter discovery cycles, 20x more candidates, and up to 100x higher binding strength versus conventional methods.

MOLCURE monetizes through enterprise B2B collaborative research agreements and AI platform licensing, offering four collaboration models: full-cycle screening/NGS/AI analysis, AI-powered de novo discovery, AI-driven lead optimization, and consulting-based problem solving. The company targets large and mid-size pharmaceutical companies as its primary segment, with biotechnology companies as a secondary segment, selling through direct enterprise sales, industry partnering conferences (BioJapan, BIO International Convention, PEGS Boston), and webinars. Disclosed customers include Boehringer Ingelheim, Fujifilm, Teijin Pharma, Ono Pharmaceutical, KM Biologics, Nippon Chemiphar, and Twist Bioscience, totaling 19 partner companies across 28 collaborative projects as of 2026.

The company is privately held and venture-backed, having raised approximately $12 million cumulatively through Series C funding led by JAFCO Group in August 2021, with participation from STRIVE, SBI Investment, Japan Post Capital, GMO VenturePartners, Dai-ichi Life, Nippon Chemiphar, and UTEC. Leadership comprises CEO/CSO Satoshi Tamaki, founder/CIO Ryu Ogawa, Chief AI Officer Batsergelen Myagmar, and Senior Advisor Han Lim (formerly CBO at Atomwise and DeepCure). MOLCURE continues to add strategic partnerships and expand geographically, including its 2026 push into US markets via BIO International Convention participation and a Hitachi co-created confidential AI infrastructure platform.

Name

Molcure

Legal name

MOLCURE Inc.

Website

https://molcure.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

11–50 employees

Short description

MOLCURE is a Japanese AI-driven drug discovery company that combines a proprietary Antibody LLM, physics-based simulations, and an in-house biolab to design antibodies and peptides for enterprise pharmaceutical and biotechnology partners via collaborative research agreements.

Ownership category

akta.pro rank

Product category

AI-Driven Biologics Drug Discovery

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

akta.pro secondary industries

AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO), Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries) (HLAAAIAL)

Keywords

• AI drug discovery
• Antibody discovery platform
• Peptide discovery
• Biologics design
• AI biotherapeutics

Headquarters

HQ city

Tokyo

HQ country

Japan

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Collaborative Research Agreements: MOLCURE generates revenue through co-development agreements with pharmaceutical companies where they apply their AI platform to discover and optimize drug candidates for specific targets. These are typically multi-year research partnerships with milestone-based payments.
2. AI Platform Licensing: Licensing of proprietary AI technologies and platform capabilities to pharmaceutical and biotech partners for drug discovery applications.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

MOLCURE provides AI-driven antibody and peptide drug discovery services through a proprietary platform that integrates a biological Large Language Model, physics-based simulations, and high-quality experimental data generated in its in-house automated BioLab. The company engages pharmaceutical and biotechnology partners via multi-year collaborative research agreements covering end-to-end molecular design, AI-powered de novo discovery, lead optimization, and consulting, enabling discovery of high-affinity biotherapeutics against challenging targets.

Product overview

MOLCURE operates as an AI-driven drug discovery company offering a unified platform approach centered on the AI Antibody Discovery Platform. This core platform combines proprietary large language models built from scratch, physics-based simulations, and high-quality experimental data from an in-house biolab containing over 1 billion proprietary molecular datapoints. The platform is accessible through four distinct collaboration models: (1) Screening, NGS, and AI Analysis for end-to-end molecular design support, (2) AI-Powered de novo Discovery for novel molecule identification, (3) AI-Driven Lead Optimization for improving candidate molecules, and (4) Consulting-Based Problem Solving for expert guidance on AI adoption in drug discovery.

Differentiator

Problem solved

Functional benefit

Products and services

• AI Antibody Discovery Platform AI-driven antibody and peptide discovery platform combining proprietary large language models built from scratch for biological data, physics-based simulations, and high-quality experimental data from MOLCURE's in-house BioLab. Used by pharmaceutical and biotechnology partners to discover effective biotherapeutics against challenging targets.
• AI-Powered de novo Antibody/Peptide Discovery Service Collaborative service in which MOLCURE uses its proprietary AI technologies to discover novel antibody and peptide molecules from partner-provided samples, enabling exploration of previously difficult or undruggable targets. Delivered to enterprise pharmaceutical and biotech R&D teams.
• AI-Driven Lead Optimization Service Collaborative service enabling pharmaceutical and biotech partners to optimize their own candidate molecules using MOLCURE's AI-based lead optimization platform, generating molecules with up to 100x higher binding strength than conventional methods.
• AI Drug Discovery Consulting Service Consulting service providing expert guidance to pharmaceutical and biotech partners on leveraging AI technologies to accelerate and enhance their drug discovery processes.

Quantifiable outcome

• Drug candidate discovery cycle reduced to 1/10th of conventional timelines
• +2 more outcomes

Named customers7 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature5 records

Partnerships

Nine partnerships are on record, tiered minor, core and flagship.

• IlluminaminorGTM or Marketing Partner · 16 June 2026MOLCURE's CIO Ryu Ogawa spoke at an Illumina-hosted webinar on AI antibody drug discovery, highlighting case studies combining MOLCURE's AI with Illumina's next-generation sequencers.
• HitachicoreTechnology or Integration · 16 April 2026MOLCURE and Hitachi announced full-scale co-creation toward launching a confidential AI platform for AI-driven drug discovery. Hitachi is developing the confidential AI infrastructure while MOLCURE provides the drug discovery AI capabilities.
• KM BiologicscoreStrategic or Co-development Partner · 28 January 2026MOLCURE and KM Biologics entered into a research agreement for AI-powered discovery of next-generation biopharmaceuticals. The partnership aims to create innovative drugs in the blood disease area using MOLCURE's AI drug discovery platform.
• Teijin PharmacoreStrategic or Co-development Partner · 7 January 2026MOLCURE signed a new agreement with Teijin Pharma to continue joint research using MOLCURE's AI platform for drug discovery.
• FujifilmcoreStrategic or Co-development Partner · 30 October 2025MOLCURE entered into a joint research agreement with Fujifilm Corporation to advance peptide discovery technology using MOLCURE's AI platform.
• Boehringer IngelheimflagshipStrategic or Co-development Partner · 7 October 2025MOLCURE entered into a multi-year strategic research agreement with Boehringer Ingelheim to discover and develop innovative antibody drugs for multiple targets using MOLCURE's AI-driven platform technology. This represents one of MOLCURE's most significant pharmaceutical partnerships.
• Ono PharmaceuticalcoreStrategic or Co-development Partner · 23 March 2023MOLCURE and Ono Pharmaceutical entered into a drug discovery collaboration agreement to discover and develop innovative antibody drugs for multiple targets using MOLCURE's AI-driven platform technology.
• Twist BiosciencecoreStrategic or Co-development Partner · 26 July 2021Twist Bioscience incorporated MOLCURE's AI technology to augment their therapeutic antibody discovery efforts. The partnership successfully produced potent binding antibodies against undisclosed cancer targets.
• FRONTEOcoreStrategic or Co-development Partner · 29 March 2021MOLCURE and FRONTEO signed a basic agreement on business alliance to promote drug discovery DX using AI. FRONTEO handles target discovery and selection while MOLCURE handles molecular design, enabling rapid candidate selection and efficacy verification.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• AbCellera Biologics: Public AI-driven antibody discovery platform that partners with pharma to screen and engineer therapeutic antibodies; competes head-to-head with Molcure in the antibody discovery service space using proprietary technology and partner-funded programs.
• Generate Biomedicines: Generative AI platform for designing novel protein therapeutics, including antibodies and peptides; directly comparable in using ML/AI to create biologics against challenging targets in partnership with pharma.
• BigHat Biosciences: AI/ML-driven antibody design platform combining wet-lab high-throughput experimentation with ML; mirrors Molcure's closed-loop approach to designing safer, more effective antibody therapeutics.
• Absci: Public company offering AI-powered biologic drug discovery, including generative AI for antibody design and a high-throughput wet lab; comparable as an integrated AI-plus-lab antibody discovery partner to pharma.
• Cradle Bio: Generative AI platform for protein engineering serving biotech and pharma partners; comparable to Molcure in using generative models plus experimental validation to design novel biologics for partner pipelines.
• Adagene: Clinical-stage AI-driven antibody platform focused on oncology biologics; comparable as a company using AI/computational biology to discover and optimize therapeutic antibodies for pharma-style collaborations.

Emerging players

• Profluent Bio: AI protein design company applying large language models to protein engineering; overlaps with Molcure's proprietary Antibody LLM approach, though Profluent is earlier-stage and broader in scope.

Broad incumbents

• Schrödinger: Public AI-driven molecular simulation and drug discovery platform with a broad small-molecule focus that increasingly extends into biologics; a broader incumbent with overlapping computational drug discovery capabilities.
• Recursion Pharmaceuticals: Public AI-driven drug discovery company combining high-throughput wet-lab experimentation with ML; larger-scale platform incumbent operating across multiple therapeutic areas, including biologics-adjacent work.
• Insitro: AI-driven drug discovery company combining ML with high-throughput biology for pharma partners; broader incumbent with overlapping AI-plus-lab infrastructure approach, though focused more on small molecules and disease modeling.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/molcure
• Facebookfacebook.com/molcure
• LinkedInlinkedin.com/company/molcure

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds6 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Molcure